Jahr Robert Charles 4

What Happened
Robert Charles Jahr, CEO of Outlook Therapeutics (OTLK), was granted a stock option for 100,000 shares on July 21, 2026. The filing reports $0 cash paid for the award (derivative grant) and the option vests and becomes exercisable in full on July 21, 2027, subject to continued service.

Key Details

• Transaction date: July 21, 2026; Form 4 filed July 23, 2026 (timely filing).
• Transaction type: Award/Grant of a stock option (derivative). Reported amount: 100,000 shares at $0.00 (no cash exchanged in this grant).
• Vesting: Vests and becomes exercisable in full on July 21, 2027, conditioned on Mr. Jahr's continued service (per footnote).
• Plan/Agreement: Granted pursuant to the Issuer’s 2024 Equity Incentive Plan and standard stock option agreement.
• Shares owned after transaction: Not specified in this filing.
• No indication of immediate exercise or sale of shares.

Context
This is a standard option grant as part of executive compensation. It is not an exercise or open‑market purchase/sale and therefore does not reflect an immediate cash transaction or sale of shares. Such grants are common for retention and incentive purposes; avoid assuming this signals a short‑term market view.